Immunogenicity and Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra) in Subjects Aged 9 to 23 Months in India and in the Russian Federation

Trial Profile

Immunogenicity and Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra) in Subjects Aged 9 to 23 Months in India and in the Russian Federation

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 25 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 27 Aug 2016 New source has been identified and integrated (Clinical Trials Registry - India;CTRI2014-12-005272).
    • 03 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top